Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Revenue (2016 - 2025)

ImmunityBio (IBRX) has disclosed Revenue for 12 consecutive years, with $38.3 million as the latest value for Q4 2025.

  • Quarterly Revenue rose 406.95% to $38.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $113.3 million through Dec 2025, up 668.31% year-over-year, with the annual reading at $113.3 million for FY2025, 668.31% up from the prior year.
  • Revenue for Q4 2025 was $38.3 million at ImmunityBio, up from $32.1 million in the prior quarter.
  • The five-year high for Revenue was $38.3 million in Q4 2025, with the low at $14000.0 in Q1 2022.
  • Average Revenue over 5 years is $6.5 million, with a median of $239000.0 recorded in 2021.
  • The sharpest move saw Revenue tumbled 89.93% in 2022, then surged 41192.5% in 2025.
  • Over 5 years, Revenue stood at $390000.0 in 2021, then plummeted by 81.28% to $73000.0 in 2022, then surged by 90.41% to $139000.0 in 2023, then surged by 5333.09% to $7.6 million in 2024, then surged by 406.95% to $38.3 million in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $38.3 million, $32.1 million, and $26.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.